2 researched Oncology entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Precision Medicine Group is stuck in a commodity CRO trap—competing on price against IQVIA, ICON, and Parexel while watching oncology budgets tighten post-Blackstone/H&F ownership. The 2026 fix: anchor revenue to real-world-ev…
Read full answer ↗Direct Answer: McKesson's real issue isn't revenue growth—US Pharma is up 18% YoY to $327.7B (fiscal 2025, 10-K). The problem is margin dilution from GLP-1 scale and Medical-Surgical Solutions near-flatline (1% growth to $11.4B). A CRO woul…
Read full answer ↗